Literature DB >> 33393045

MicroRNA-593-3p Expression in Peritoneal Lavage Fluid as a Prognostic Marker for Pancreatic Cancer Patients Undergoing Staging Laparoscopy.

Tatsuo Hata1, Masamichi Mizuma2, Kunihiro Masuda2, Kazuharu Chiba2, Masaharu Ishida2, Hideo Ohtsuka2, Kei Nakagawa2, Takanori Morikawa2, Takashi Kamei2, Michiaki Unno2.   

Abstract

BACKGROUND: Some presumed resectable pancreatic cancer patients harbor radiographically occult metastases that are incidentally identified at the time of abdominal exploration. This study aims to identify novel diagnostic or predictive microRNA (miRNA) markers for subclinical peritoneal dissemination in patients with pancreatic cancer undergoing abdominal exploration.
METHODS: Peritoneal lavage fluid samples were harvested from 74 patients with pancreatic cancer at the time of staging laparoscopy. Microarray analysis was performed using peritoneal lavage fluids with positive and negative cytology. Candidate microRNA expression was quantified and validated by droplet-digital PCR assays.
RESULTS: In the miRNA array analysis, miR-593-3p showed significant upregulation in peritoneal lavage fluids with positive cytology. Of the 74 patients validated, peritoneal lavage fluids with positive cytology had significantly higher expression of miR-593-3p than those with negative cytology (P < 0.001). Even in cases with no peritoneal dissemination and negative cytology, multivariate analysis revealed that elevated miR-593-3p expression was significantly correlated with worse overall survival than those with low expression (hazard ratio: 3.474, P = 0.042). Of the 48 patients who underwent pancreatectomy, multivariate analysis also demonstrated that higher expression of miR-593-3p in peritoneal lavage was the only significant poor prognostic marker influencing both overall survival (hazard ratio: 23.38, P = 0.005) and recurrence-free survival (hazard ratio: 5.700, P = 0.002).
CONCLUSIONS: Elevated miR-593-3p expression in peritoneal lavage suggests the presence of subclinical micrometastasis even in cases with localized pancreatic cancer, and miR-593-3p could be a useful prognostic predictor for pancreatic cancer patients undergoing staging laparoscopy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33393045     DOI: 10.1245/s10434-020-09440-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases.

Authors:  Tatsuyuki Takadate; Takanori Morikawa; Masaharu Ishida; Shuichi Aoki; Tatsuo Hata; Masahiro Iseki; Takayuki Miura; Kyohei Ariake; Shimpei Maeda; Kei Kawaguchi; Kunihiro Masuda; Hideo Ohtsuka; Masamichi Mizuma; Hiroki Hayashi; Kei Nakagawa; Fuyuhiko Motoi; Takashi Kamei; Takeshi Naitoh; Michiaki Unno
Journal:  Surg Today       Date:  2020-09-08       Impact factor: 2.549

  1 in total
  2 in total

Review 1.  Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review.

Authors:  Susana Olmedillas-López; Rocío Olivera-Salazar; Mariano García-Arranz; Damián García-Olmo
Journal:  Mol Diagn Ther       Date:  2021-11-13       Impact factor: 4.074

2.  miR-593-3p Promotes Proliferation and Invasion in Prostate Cancer Cells by Targeting ADIPOR1.

Authors:  Qiang Huang; Long Peng; Yuxiang Sun; Jiayu Huang; Tong Han; Yongjie Li; Hui Peng
Journal:  Onco Targets Ther       Date:  2021-06-14       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.